RADIOACTIVE IODINE THERAPY

1946/12/07 by S. M. SEIDLIN, S. M. Seidlin · 27 citations
Medicine · #Thyroid Cancer Diagnosis and Treatment #Pituitary Gland Disorders and Treatments #Thyroid Disorders and Treatments

paper · doi:10.1001/jama.1946.02870490016004

Abstract

Therapy of neoplastic disease usually consists of two phases: first, the treatment of the primary focus and, second, that of metastases. Specifically, in adenocarcinoma of the thyroid, the primary site together with its immediate extensions is conventionally treated by surgery, radiation or both. Distant metastases, if treated, are usually subjected to palliative external irradiation. This paper is a report of successful therapy of a case of metastatic adenocarcinoma of the thyroid treated by the principle of specific internal irradiation with radioactive iodine. The earliest study of the uptake of radioactive iodine in 2 cases of carcinoma was reported by Hamilton and his associates¹in 1940. In 1942 he described 2 more cases²in which tracer doses of radioactive iodine had been given to the patients prior to the removal of carcinomatous thyroids. Radioautographs of the excised glands showed no significant deposition of the radioactive iodine in malignant areas

Cited by

• The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications
• Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
• Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. [europepmc]
• 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. [europepmc]
• Physiological sodium concentrations enhance the iodide affinity of the Na+/I- symporter. [europepmc]
• 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. [europepmc]
• Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. [europepmc]
• The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. [europepmc]
• Saul Hertz, MD, and the birth of radionuclide therapy. [europepmc]
• Theranostic radiopharmaceuticals: established agents in current use. [europepmc]
• Recent advances in theranostics and challenges for the future. [europepmc]
• Advancing Targeted Radionuclide Therapy Through the National Cancer Institute's Small Business Innovation Research Pathway. [europepmc]
• Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers. [europepmc]
• Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning. [europepmc]
• Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. [europepmc]
• Multifocal papillary thyroid cancer in children and adolescents: 12-year experience in a single center. [europepmc]
• Radiotheranostics: a roadmap for future development. [europepmc]
• Allosteric regulation of mammalian Na + /I - symporter activity by perchlorate. [europepmc]
• A Review of the History of Radioactive Iodine Theranostics: The Origin of Nuclear Ontology [europepmc]
• Celebrating eighty years of radionuclide therapy and the work of Saul Hertz. [europepmc]
• Radio-Iodide Treatment: From Molecular Aspects to the Clinical View. [europepmc]
• Advances in Functional Imaging of Differentiated Thyroid Cancer. [europepmc]
• AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. [europepmc]
• Redox Homeostasis in Thyroid Cancer: Implications in Na + /I - Symporter (NIS) Regulation. [europepmc]
• Radiotheranostics in oncology: current challenges and emerging opportunities. [europepmc]
• RET kinase inhibitors for RET -altered thyroid cancers. [europepmc]
• Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy. [europepmc]

Related

• Detection of Functioning Thyroid Cancer Metastasis on Whole Body Pertechnetate Scintigraphy.
• Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis
• Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
• Trends in metastatic thyroid cancer survival from 1992 to 2022: a SEER database analysis
• Controversies, Consensus, and Collaboration in the Use of 131 I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association